New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemnt Compared To Intraveous Therapy
Links shared publicly online about this topic.
- 737total visits
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemnt Compared To Intraveous Therapy
(NYSE:BMY) announced that new Phase III clinical data show that a weekly subcutaneous injection of an investigational formulation of ORENCIA® (abatacept), following a single intravenous (I.V.)
View full resource at medicalnewstoday.com
Tags: Rheumatoid Arthritis Medication, Orencia
Most Recently Shared on November 10, 2010 at 8:05 pm By:
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemn... http://mnt.to/3Mm7
Also Shared By:
Advertisement
MNT Arthritis News
@mnt_arthritis
New Data Show That Subcutaneous Injection Of An Investigational Formulation Of ORENCIA® Provided Similar Improvemn... http://mnt.to/3Mm7
1 year ago...